Latest Erlotinib Stories
SAN DIEGO, May 26, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc.
OMAHA, Neb., May 26, 2011 /PRNewswire/ -- Transgenomic, Inc.
RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
BROOMFIELD, Colo., April 28, 2011 /PRNewswire/ -- Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as "Alchemy").
Two sets of gene expression profiles predict response to a common lung cancer drug for patients that have no guiding indicators for their treatment now.
WALTHAM, Mass., March 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.
NEW YORK, March 31, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a development stage, specialty pharmaceutical and medical device company focused on oncology, announced today the appointment of Gabriel Leung, M.Sc. to the Company's expanded Board of Directors, effective immediately.
LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients.
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.
- a slit in a tire to drain away surface water and improve traction.